Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    Chen M, Zhuang J, Yang C, Zhang L, Wang W, Cai H, Yu Y, Li J, Zhou D, Han B (2020) Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol 99:1141–1143

    Article  Google Scholar 

  2. 2.

    Fadlallah J, Michel M, Crickx E, Limal N, Costedoat N, Malphettes M, Fieschi C, Galicier L, Oksenhendler E, Godeau B, Audia S, Mahévas M (2019) Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol 187:124–128

    CAS  Article  Google Scholar 

  3. 3.

    Knight T, Ravindranath Y, Callaghan MU (2020) Successful treatment of an adolescent male with severe refractory evans syndrome using bortezomib-based. Therapy J Pediatr Hematol Oncol 42:110–113

    Article  Google Scholar 

Download references

Author information




SJ and PRJA reviewed the data, SJ drew the graphs, and PRJA wrote the article that SJ reviewed and approved.

Corresponding author

Correspondence to Paul R. J. Ames.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

The patient gave written consent for her case to be published on a medical journal.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ames, P.R.J., Jeffrey, S. Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia. Ann Hematol (2020).

Download citation